The course of nausea and vomiting after high-dose cyclophosphamide.
The course of nausea and vomiting after high-dose cyclophosphamide.
复制标题
大剂量环磷酰胺后恶心呕吐的过程。
DOI：
--
复制
发表时间：
1982
期刊：
影响因子：
--
通讯作者：
M. Colvin
中科院分区：
文献类型：
--
作者：
J. Fetting;L. Grochow;M. Folstein;D. Ettinger;M. Colvin
我们研究了 25 名患者服用高剂量环磷酰胺（50-75 mg/kg）后恶心和呕吐的过程。恶心通过视觉模拟量表进行评估，呕吐通过患者报告进行评估。这些评估方法的可靠性和有效性是在针对肿瘤患者的单独研究中确定的。大约三分之二的患者在开始 1 小时环磷酰胺输注后 6 至 12 小时内出现恶心和呕吐。症状高峰出现在 12 小时。 24 小时后，大多数患者的呕吐症状已经减轻，但恶心仍然持续。尽管恶心和呕吐的过程存在显着的个体差异，但我们无法确定与更严重的恶心和呕吐相关的人口统计学、疾病、药物或治疗因素。恶心和呕吐的发作、严重程度和持续时间的一些变异性可能与环磷酰胺代谢和敏感性的个体差异有关。视觉模拟量表可以提供有关恶心的信息，而这些信息是通过更常用的分类言语评级量表无法获得的。根据研究结果提出了大剂量环磷酰胺后恶心和呕吐的治疗建议。
We studied the course of nausea and vomiting after high-dose cyclophosphamide (50-75 mg/kg) in 25 patients. Nausea was assessed with a visual analog scale and vomiting by patient report. The reliability and validity of these methods of assessment were established in separate studies of oncology patients. Nausea and vomiting developed between 6 and 12 hours after the start of a 1-hour cyclophosphamide infusion in about two thirds of the patients. Peak symptoms were at 12 hours. Vomiting had subsided in most of the patients by 24 hours, but nausea persisted. Although there was significant individual variation in the course of nausea and vomiting, we could identify no demographic, disease, drug, or treatment factors which were associated with more significant nausea and vomiting. Some of the variability in the onset, severity, and duration of nausea and vomiting may be related to individual differences in the metabolism of and susceptibility to cyclophosphamide. The visual analog scale may provide information about nausea not obtained by the more frequently employed categoric verbal rating scales. Suggestions for the treatment of nausea and vomiting after high-dose cyclophosphamide are made on the basis of the findings.